Plasma sphingosine-1-phosphate is elevated in obesity.

BACKGROUND: Dysfunctional lipid metabolism is a hallmark of obesity and insulin resistance and a risk factor for various cardiovascular and metabolic complications. In addition to the well known increase in plasma triglycerides and free fatty acids, recent work in humans and rodents has shown that o...

Full description

Bibliographic Details
Main Authors: Greg M Kowalski, Andrew L Carey, Ahrathy Selathurai, Bronwyn A Kingwell, Clinton R Bruce
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3765451?pdf=render
_version_ 1818177714624921600
author Greg M Kowalski
Andrew L Carey
Ahrathy Selathurai
Bronwyn A Kingwell
Clinton R Bruce
author_facet Greg M Kowalski
Andrew L Carey
Ahrathy Selathurai
Bronwyn A Kingwell
Clinton R Bruce
author_sort Greg M Kowalski
collection DOAJ
description BACKGROUND: Dysfunctional lipid metabolism is a hallmark of obesity and insulin resistance and a risk factor for various cardiovascular and metabolic complications. In addition to the well known increase in plasma triglycerides and free fatty acids, recent work in humans and rodents has shown that obesity is associated with elevations in the bioactive class of sphingolipids known as ceramides. However, in obesity little is known about the plasma concentrations of sphinogsine-1-phosphate (S1P), the breakdown product of ceramide, which is an important signaling molecule in mammalian biology. Therefore, the purpose of this study was to examine the impact of obesity on circulating S1P concentration and its relationship with markers of glucose metabolism and insulin sensitivity. METHODOLOGY/PRINCIPAL FINDINGS: Plasma S1P levels were determined in high-fat diet (HFD)-induced and genetically obese (ob/ob) mice along with obese humans. Circulating S1P was elevated in both obese mouse models and in obese humans compared with lean healthy controls. Furthermore, in humans, plasma S1P positively correlated with total body fat percentage, body mass index (BMI), waist circumference, fasting insulin, HOMA-IR, HbA1c (%), total and LDL cholesterol. In addition, fasting increased plasma S1P levels in lean healthy mice. CONCLUSION: We show that elevations in plasma S1P are a feature of both human and rodent obesity and correlate with metabolic abnormalities such as adiposity and insulin resistance.
first_indexed 2024-12-11T20:36:29Z
format Article
id doaj.art-3db048d0465e417f8462f6dcd800ca20
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-11T20:36:29Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-3db048d0465e417f8462f6dcd800ca202022-12-22T00:51:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0189e7244910.1371/journal.pone.0072449Plasma sphingosine-1-phosphate is elevated in obesity.Greg M KowalskiAndrew L CareyAhrathy SelathuraiBronwyn A KingwellClinton R BruceBACKGROUND: Dysfunctional lipid metabolism is a hallmark of obesity and insulin resistance and a risk factor for various cardiovascular and metabolic complications. In addition to the well known increase in plasma triglycerides and free fatty acids, recent work in humans and rodents has shown that obesity is associated with elevations in the bioactive class of sphingolipids known as ceramides. However, in obesity little is known about the plasma concentrations of sphinogsine-1-phosphate (S1P), the breakdown product of ceramide, which is an important signaling molecule in mammalian biology. Therefore, the purpose of this study was to examine the impact of obesity on circulating S1P concentration and its relationship with markers of glucose metabolism and insulin sensitivity. METHODOLOGY/PRINCIPAL FINDINGS: Plasma S1P levels were determined in high-fat diet (HFD)-induced and genetically obese (ob/ob) mice along with obese humans. Circulating S1P was elevated in both obese mouse models and in obese humans compared with lean healthy controls. Furthermore, in humans, plasma S1P positively correlated with total body fat percentage, body mass index (BMI), waist circumference, fasting insulin, HOMA-IR, HbA1c (%), total and LDL cholesterol. In addition, fasting increased plasma S1P levels in lean healthy mice. CONCLUSION: We show that elevations in plasma S1P are a feature of both human and rodent obesity and correlate with metabolic abnormalities such as adiposity and insulin resistance.http://europepmc.org/articles/PMC3765451?pdf=render
spellingShingle Greg M Kowalski
Andrew L Carey
Ahrathy Selathurai
Bronwyn A Kingwell
Clinton R Bruce
Plasma sphingosine-1-phosphate is elevated in obesity.
PLoS ONE
title Plasma sphingosine-1-phosphate is elevated in obesity.
title_full Plasma sphingosine-1-phosphate is elevated in obesity.
title_fullStr Plasma sphingosine-1-phosphate is elevated in obesity.
title_full_unstemmed Plasma sphingosine-1-phosphate is elevated in obesity.
title_short Plasma sphingosine-1-phosphate is elevated in obesity.
title_sort plasma sphingosine 1 phosphate is elevated in obesity
url http://europepmc.org/articles/PMC3765451?pdf=render
work_keys_str_mv AT gregmkowalski plasmasphingosine1phosphateiselevatedinobesity
AT andrewlcarey plasmasphingosine1phosphateiselevatedinobesity
AT ahrathyselathurai plasmasphingosine1phosphateiselevatedinobesity
AT bronwynakingwell plasmasphingosine1phosphateiselevatedinobesity
AT clintonrbruce plasmasphingosine1phosphateiselevatedinobesity